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Antibiotics- Effective Indefinitely?

Antibiotics and Antibiotic Resistance

Perhaps one of the most innovative medical inventions mankind has developed is the
antibiotic. Since 1936, antibiotics have been able to combat bacterial infections that led to death,
which accounted for 30 percent of deaths at that time [1]. The mechanism that antibiotics have
adopted when terminating bacteria involves breaking down the bacteria cell wall made of rigid
peptidoglycans, a material made of amino acids and carbohydrates that assist in the stability and
protection of the cell. Once the breach has commenced, metabolic and enzymatic functions are
further disrupted as well as DNA replication. Like most cells, these functions are essential when
considering normal cell processes.
Though antibiotics have proven time and time again to be useful to treat common
bacterial infections, this is a treatment that unfortunately will not be in use indefinitely. As a
matter of fact, antibiotics can become ineffective for most of the human population by as early as
the year 2050, a great deal sooner than most would expect, especially for a medical discovery
that has saved lives for many years. Unfortunately, incidences of antibiotic-resistant infections
have already risen across the country, and the “CDC found that antibiotic-resistant pathogens
cause more than 2.8 million infections in the U.S. each year and more than 35,000 people die”
[12]. Though it may not seem like a problem now, antibiotic resistance-caused infections will
make COVID-19 look like a mere sneeze in comparison. Bacteria are microscopic organisms
that are just as alive as any other living and breathing organism. With that being said, bacteria
have the ability to mutate across their genome and adapt to their ever-changing environment.
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Survival of the fittest. When bacteria adapt, they may incorporate a phenomenon known as
antibiotic resistance. Over time, antibiotics will become less effective against bacterial
infections, seen in Figure 1.1, sending the human race a hundred years back. Deaths will rise,
surgeries will become critically intensive to prevent bacterial infection, and everyday life will
change as the world knows it. How can science change the course of this future catastrophe?

Figure 1.1- “How does antibiotic resistance occur? [15].

Bacteriophages

Thankfully, Mother Nature has provided a solution. Some researchers have started to
work with viruses called bacteriophages, or phages more commonly. Unlike bacteria, phages are
non-living entities that require a host for living and replication. Not all bacteriophages can
terminate all bacteria cells. Phages have to go through a matching process to find a bacteria that
they may infect; otherwise, a bacteria cell may present surface features and enzymatic functions
that protect it from infection by a phage. Even though this is true, phages greatly outnumber the
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number of bacteria present in the world almost ten to one, giving them a promising chance for a
match. The common structure of a bacteriophage consists of three major segments. First is the
20-sided head that contains DNA or RNA, the genetic material that contains the genome of the
phage for replication. Proteins encapsulating the headpiece provide protection for the genetic
material of the bacteriophage. The headpiece is supported by a tail, which is composed of a
center tail tube surrounded by structural proteins, which join together at a protein base plate at
the bottom. Lastly, tail fibers extend from the base plate and act as legs for the phage, allowing
for the ability to latch onto bacteria cells [2]. Phages attach themselves to bacteria cells and inject
their genetic material into the cell’s cytoplasm via a process referred to as adsorption. Proteins
from the phage’s baseplate and tail assist in breaking down the cell wall of the bacteria cell to
initiate injection [32]. When the genetic material enters, it is incorporated into the bacteria cell’s
genome seen in Figure 1.2, disguising itself as part of the genome.

Figure 1.2- Injection from a bacteriophage upon a bacterial
host cell [34].
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Starting stranded in the headpiece of the phage, the genetic material becomes circularized
once it enters the bacteria cell. At this point in the bacteriophage infection process, a crossroads
emerges. Phages may enter two different phases, the lytic or lysogenic cycle. The lytic cycle is
what occurs next for the phage in most cases, in which the bacteria cell will begin to translate
viral proteins. These proteins will accumulate and begin to synthesize the head and tail pieces of
bacteriophages. After multiple phages mature from within the cell body, the cell will lyse and
release the phages, now referred to as virions, to travel and infect nearby bacteria cells just as
before. The common name bacteriophage can be somewhat misleading because the name itself
translates to “eater of bacteria.” During bacteriophage infection, phages do not perform the act of
eating or engulfing bacteria cells, but rather invade and destroy them from the inside out.

Figure 1.3- Actual representation of a bacteriophage [16].
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The other pathway a bacteriophage, seen realistically in Figure 1.3, may achieve its
mechanism through is the lysogenic cycle. In the lysogenic cycle, a bacteriophage infects the
host bacterial cell and still allows its DNA to circularize and join the host’s DNA. At this point,
instead of beginning the process of translation, as in the lytic cycle, the newly recombinant DNA,
a prophage, stays embedded and repressed through multiple divisions of the bacterial host cell.
The cell that contains a prophage is now referred to as a lysogen. As the lysogen divides along
with its prophage, all future generations contain the prophage, therefore also classifying them
also as lysogens [13]. When the appropriate time ensues, the phage genes in the prophage
activate the bacterial cell to begin the production of virion particles. Factors that promote this
transition from the lysogenic to the lytic cycle can be attributed to stressors in the form of toxic
chemicals, current living conditions that are detrimental to the host cell, as well as intense UV
light [5]. Once the virion particles have matured, the bacterial cell will lyse and release its newly
made virions into the environment to attach to more bacterial cells, likewise, just as how the
mechanism proceeds through the end of the lytic cycle of bacteriophages. Interestingly, once a
bacterial cell is infected with a specific bacteriophage entering the lysogenic cycle, phages that
have similar genomes are not able to additionally infect the already-infected host [24]. Divide
and conquer is the name of the game for these marvelous microscopic entities, with their
infection lysogenic and lytic cycles seen in Figure 1.4.
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Figure 1.4- A Diagram depicting the lysogenic and
lytic cycles, as lysogenic phages eventually end up as
lysogens [28].

Lytic vs Lysogenic: What is Better for Use?

It is important to address the fact that only bacteriophages that only go through the lytic
cycle can be used for gene therapy. A couple of factors play a part as to why this is. First off,
bacteriophage research is an up-and-coming branch of medical research, even though regulations
set by the FDA have slowed this down. To learn more about bacteriophages and what they can
offer humanity, observing and sequencing bacteriophages can provide answers that some
researchers may need to answer questions about their medical uses. Temperate phages are not
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ideal for phage therapy because of their nature to go into the lysogenic cycle, delaying their
effectiveness in what could be an immediate situation. Virulent phages are needed for phage
therapy. According to sciencedirect.com, “virulence is defined as the relative ability of a
microorganism to overcome host defenses, or the degree of pathogenicity within a group or
species DNA” [21]. Virulent phages are best for phage therapy because of their predictability in
use. Temperate phages may be in the lysogenic cycle, likewise, virulent phages are only in the
lytic cycle. “Phage therapy mainly utilizes obligately lytic phages to kill their respective bacterial
hosts,” for if temperate phages were used, it is challenging to pinpoint exactly when the
prophage will lyse to progenies, therefore affecting results for lab and clinical trials [35]. With
virulent phages, it is easier to administer and test, due to the practicality of learning the virulence
patterns of the phage itself. Overall, only virulent phages from the lytic cycle can be used for
research and clinical trial testing due to the nature of their DNA as well as the way they express
their virulence within their lytic infection cycle. The question now presented: How can
bacteriophages be incorporated to our advantage in medicine?
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Phage Therapy- An Innovation for Medication?

Phage Therapy- What is it?

Dating as far back as the early twentieth century, even before the time of renowned
antibiotics, bacteriophages have been studied for their medical purposes by physicians and
researchers alike. Phage therapy is a treatment that has helped millions of people around the
world throughout time. In the beginning, these studies and treatments have taken place for the
most part in European countries. This is mostly due to strict restrictions imposed by the United
States Food and Drug Administration (FDA), which only allows patients to receive treatment
with phages via compassionate use based on the severity of the case and/or the limited number of
options for the patient’s care [23]. Over time, the FDA has begun to ease restrictions on phage
research and use in the United States, paving the road little by little for possible future use of
phages pertaining to many medical aspects.
During trials for phage therapy treatment, it has been widely observed that phages have
successfully been administered through the nasal cavity, intravenously, topically, and orally. It is
key that the phages reach the bloodstream to reach the correct target site. Recent studies have
shown that phages have the capability to transition from the gut to the bloodstream via epithelial
cells in the stomach lining [8]. With the adroitness of bacteriophage administration, this medical
treatment could very well be sold on a store shelf or as a prescription as an effortless way to treat
bacterial infection and disease in the future. One such case was studied involving a 68-year-old
man in California suffering from a life-threatening case of pancreatic pseudocyst caused by a
resistant bacterial strain named Acinetobacter baumannii. The patient's physicians had attempted
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to treat him with antibiotics for over four months, but unfortunately, the conditions of the patient
had worsened, leading to further complications such as respiratory and renal failure. With the
severity of the situation at hand, permission to administer phage therapy had been given to
physicians and researchers by the FDA. Thankfully, after receiving phage therapy targeting the
specific type of bacteria percutaneously and intravenously, the patient achieved a remarkable
recovery. It was also noted that the patient had experienced no adverse effects to high toxicity or
bodily rejection from the phages that had been administered to him [9]. Promising medical cases
involving phage therapy such as this account further accredit the stance that bacteriophages are
safe and effective treatments that could be the answer to the plight pertaining to antibiotic
resistance.
Many benefits are involved with phage therapy in the world of medicine. Firstly,
bacteriophages are naturally occurring and cost-effective, when considered from an economic
perspective. Based on the mechanisms phages exhibit when terminating bacteria, they may have
the capability to only need to be administered in one or a low number of doses. In addition, the
administered phages do not disturb normal gut flora or cause high toxicity levels in the body,
rendering them safe for human use. Unlike antibiotics, phages have the ability to evolve and
adapt parallel to their bacterial counterparts, eliminating the question of bacteriophage resistance
down the road [10]. On the other hand, phage therapy, like all medical treatments, still presents
its downfalls. Bacteriophages, being target-specific, may at times require extensive searches to
find a match for a targeted bacterial strain. As far as widespread development and administration,
the problem regarding the correct concentration and duration of phage therapy is still taken into
consideration, though this will eventually resolve itself in time as research is completed by more
and more of those diving into the world of phage therapy [11]. Answering the basic question of
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“How much phage do I use?” is a decent start for continuing on into other phage research
projects.

Regulations and Rise to Popularity

Figure 2.1- The FDA for the United States (left) and the EMA for Europe (right), are the
main administrations that regulate what goes as far as phage research and therapy, for their
respective locations [31, 29].

For the United States, phages are regulated under the FDA, seen in Figure 2.1, while in
Europe, where phages have made the most headway, they are regulated under EMA, the
European Medicine Agency. “Since 2011, the phages have been classified as drugs in the US and
as medicinal product in EU;” therefore, phages are seen as “a substance or combination of
substances that is intended to treat, prevent or diagnose a disease, or to restore, correct or modify
physiological functions by exerting a pharmacological, immunological or metabolic action.” By
this definition, the EMA allows more relaxed regulation for phages as opposed to the FDA. The
EMA has also been able to obtain survey data that states “approximately 60 experts from
academia, industry, policymakers and patient organizations discussed practical and regulatory
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issues in obtaining a license to develop bacteriophage-based therapies against bacterial
infections'', making it relatively a highly requested area of study to receive easier regulations to
broaden research opportunities [38]. Phage therapy performed by medical research laboratories
and universities mainly receives funding through different groups such as the National Science
Foundation or the National Institutes of Health, to name a couple.

Figure 2.2- A diagram depicting the worldwide applicants for
patents related to phage research in 2002 [4].

As seen in Figure 2.2, two takeaways provide a credible answer as to whether phage
research is popular enough, not only in the United States or Europe but in all nations of the
whole world. As shown in green, China has actually been the front-runner for nations when it
comes to patents for phage technologies. These technologies go on to provide testable phages for
medical lab and medical clinical trials. This chart also allows one to see that many countries and
their institutions are involved in phage research, being seventeen shown having an average of
about 15 patents since 2002. Research into the use of bacteriophages as a potential replacement
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for antibiotics is viewed as an important issue that could be easily solved, paving the road to the
future of medicine, not only for the United States but for all citizens of the world.

Figure 2.3- “PubMed search results for ‘phage therapy’ or ‘bacteriophage therapy’
across time periods” [17].

The biggest factor that is hindering phage research from receiving more grants, is that,
paradoxically, not many phage research projects have received grants. On the other hand, Figure
2.3 demonstrates the fact that interest in phage therapy has risen quite significantly over the last
few decades. This only helps the push for more regulations towards phage research to be lifted
by the FDA in the United States. When more phage therapy is allowed to be conducted, more
answers about phages and how they can help mankind may be answered, the most obvious
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waiting to be answered: What are the positive and negative attributes to phages being used in
medicine? Phage interest is expected to increase in the years to come as well as the millions of
dollars expected to turn a profit from phage research and clinical trials.

Cost-Effectively Beneficial for All

Methicillin-resistant Staphylococcus aureus (MRSA) is a resistant bacteria that infects
thousands of Americans a year. To treat this infection, which has a mortality rate of 24%, one
would have to pay about $35,000. This type of treatment may utilize a different antibiotic
prescribed than the known ineffective one by the patient’s physician. The downside, the new
antibiotic may also not be effective enough to the bacteria due to complete resistance and instead
could potentially attack other bacteria that abide within the body through a mutualistic
relationship. The antibiotic could also have too much of an effect on the MRSA bacteria, also
killing too much neighboring good bacteria [18]. If the resistant bacteria were to be treated by
means of phage therapy, then the cost of treatment would be substantially lower compared to the
antibiotic method. In the country of Georgia, “an American-owned subsidiary, which is bringing
foreign patients to Tbilisi for phage treatments on diabetic foot, burns, ulcers, osteomyelitis, and
drug-resistant infections such as MRSA,” has “a course of treatment [that] costs between $8,000
and $20,000." The company has now gone as far as to open another clinal branch in Mexico on
the opposite side of the world, therefore decreasing the cost of treatment and trip to an even
lower amount owed for patients [33].
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Figure 2.4- An oral/topical bacteriophage treatment
from Georgia, usually costing a fraction of the price
as antibiotics [3].

As one may see, the overall price for treating bacterial infections, especially ones that are
resistant, may come out to be much cheaper for patients that are using phage therapies. By being
administered bacteriophages, most likely orally through a pill or liquid form, as seen in Figure
2.4, patients will be able to experience not only an effective treatment compared to antibiotics in
the future, but also a cheaper one. There may be many languages and tongues spoken among the
people of the world, but everyone speaks money, so naturally, a cheaper treatment is going to be
more favored among the general public. Since phage therapy would be regulated by the FDA,
pharmaceutical companies, like with all forms of medication and treatments today, may increase
or decrease the price of phage therapy. Either way, phage therapy is going to be cheaper than the
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alternative. From an economical sense, the switch-over to using phage therapy will also greatly
benefit the lower-class and those living in poverty. In some areas, many can not afford to live in
healthy conditions with clean drinking and bathing water, which is also used as a toilet for some,
making matters worse in terms of potential bacterial infection. With these many instances of
uncleanliness, newly-formed and persistent bacteria have the opportunity to infect people and
animals in the environment, causing them great illnesses such as infections or cholera.

A Mutualistic Relationship

Astonishingly, dwelling within the human body are millions and millions of bacteria
cells. In fact, there are as many as ten times the amount of bacteria cells in the human body than
there are normal cells. There is no need to worry though: these are usually types of bacteria that
“help to digest substances that the human body cannot break down, like many carbohydrates and
things called short-chain fatty acids” [19]. When referring to these bacteria, scientists often use
the term “gut-flora” if the topic of discussion is centered around these mutualistic bacterial cells
that live in the human digestive tract. Many types of bacteria, as many 800 different species may
thrive at a time. To counteract this, past research has shown that there are up to 2,800 active
bacteriophages that assist in checking and balancing the number of bacteria in the body [39].
Later mentioned, bacteriophages are matched to their bacterial counterparts in phage therapy. A
patient would ingest a phage that is designed to only be harmful to the bad bacteria in the body
versus the good bacteria that assist in many different bodily functions, as seen in Figure 2.5.
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Figure 2.5- Some different types of bacteria in the gut that
bacteriophages may kill or allow to help the body [26].

When taking advantage of phage therapy, one will not have to fret about negative effects
occurring on one’s own microbiome dwelling within them from taking bacteriophages. A patient
who experiences issues with diseases regarding the intestinal tract, unsurprisingly, has been
found to possess a larger number of bacteriophages than the average healthy person. Even
without having to bring in “big pharma,” the body is able to make a natural recovery at times due
to phages and the amazing benefits that they may offer. Phage therapy would not only broaden
the spectrum of treatments for different intestinal issues or other diseases, but it will also cause
the process to become simpler, due to the meticulous microbiological mechanism that these
bacteriophages follow.
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Bacteriophage Resistance?

No doubt, bacteriophages provide a great alternative to antibiotics, the biggest reason of
course being the end of worrying about antibiotic resistance. The biggest player in antibiotic
resistance is evolution. As bacteria grow and die from antibiotics, multiple generations that may
develop a natural immunity to the antibiotic are recycled through. Whether the natural immunity
was obtained by a direct mutation or from favorable traits being passed down progeny to
progeny is determined by observing the genetic code of the bacteria to compare to other known
bacteria that have acted similarly. Bacteria colonies that exhibit resistance will continue to live
after the susceptible bacteria die out. As these bacteria die out, they also take with them the gene
population for bacteria that are non-resistant to the antibiotics being administered. Likewise, the
genes that code for the bacteria cells to be resistant stay and are passed down through the
subsequent generations of bacterial colonies to come. This leaves only bacteria that are resistant
to live on, therefore causing antibiotic resistance of the species, making them more deadly to
humans and the environment that they may live in. One may wonder if the same problem will
happen to bacteriophages in the future through “bacteriophage-resistance,” but would be wrong
to view it as a potential problem. The great thing about bacteriophages is that they may be
matched to evolve alongside their bacterial hosts by means of “coevolving them with their hosts
for 1 month repeatedly, [which] enhances their capacity for suppressing bacterial growth and
delays the emergence of resistance” [30]. When the genome of bacteria populations is evolved to
better accommodate the bacterial cell to the environment, a change in the genetic code may be
used with lab techniques such as PCR (Polymerase Chain Reaction) to amplify a gene site in
order to determine the exact area of code that has evolved relatively for the total population.
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When researchers and scientists are able to determine this, then they may be able to make the
same change in the genetic code to the partnered bacteriophage for infection, suggesting that the
bacteriophage is evolving along with the bacteria hosts. For example, some researchers have
seen “an observed correlation between GC content of the phage genome and its host genome
[that] has been explained based on intense co-evolution” [6]. It is this process of co-evolving the
bacteriophage to its target host bacteria that ensures “bacteriophage resistance” would not
become a situation to arise in the future. Inevitably, this process will also help in preventing the
phages to attack the patient’s natural abiding gut-flora.

Host-Phage Matching

The whole process of taking a bacteria host and matching it with the appropriate and
specific bacteriophage for co-evolution can be done in two ways: code-matching and phage
training. When the bacteriophages are matched to their respective bacterial host counterparts
based on their raw natural genetic code, this is simply referred to as code-matching. Researchers
collect and amplify the code of the phage in testing. Next, matches are found that naturally exist
between phages and host bacteria. Very rarely there are instances where researchers and
scientists may take this route to better study a phage for its characteristics in regards to potential
phage therapy. In the recent world of phage research, “a new approach to produce efficient
phages by capitalizing on the evolved response of wild-type phages to bacterial resistance” has
arisen [20]. Phage training deals with the aspect of genetically altering the phage itself to better
match the code of the host bacterial cells. The code is manipulated to better suit the relationship
between the phage and the host bacteria that is being targeted. This more manual form of
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code-matching not only better prevents bacteriophage resistance, but also allows the
bacteriophage to safely and effectively work against the bacteria that it is attacking. Phage
training also assists well in designing phages to work mutually with good bacteria in the body by
keeping good bacteria concentration in check, yet not causing too much disturbance, allowing
them to benefit the body.

Figure 2.6- Phage training allows researchers to get the most
out of their experimentation. As shown here, the trained phage
acts more lysogenic, rendering research more effective [25].

After a phage is matched to its respective host bacteria, it is typically said that the
bacteria has joined the bacteriophage’s host range, which is defined as which “bacterial genera,
species, and strains it can lyse; it is one of the defining biological characteristics of a particular
bacterial virus” [22]. The mechanism by which bacteriophages find a match is by attaching to
receptors already existing on the bacteria cell’s surface. These receptors sit on the outside of the
bacterial cell wall, waiting to attach, match, and become infected by a bacteriophage in the
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environment. Host range can play a major role in phage therapy. The higher that a phage’s host
range is, then the more types of bacteria that the phage can target and destroy. Using phage
training, basic effects seen in Figure 2.6, to cause a bacteriophage to have a broader host range,
as seen in Figure 2.7, will allow phage therapy to become more effective as an overall treatment
in the long run. The more bacteria that can be targeted, the more diseases and infections that can
be treated, therefore helping more people and causing phage therapy to be an ideal route as
opposed to today’s treatments that mostly incorporate relatively time-stamped antibiotics.
Indirectly, using phages with a broader host range will also benefit physicians. Incorporating
broad-host-range phages into phage therapy will be faster and less of a hassle to treat a patient in
a critical situation since one “go-to” treatment that covers a wide range of issues can be
administered efficiently and effectively.

Figure 2.7- Larger host ranges allow phages to treat a broader range of
medical issues [37].
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Host-Phage Interactions

When using bacteriophages in phage research and phage therapy, it is necessary to
consider the phage’s multiplicity of infection or MOI for short. The MOI “literally means the
ratio of phages to bacteria when counting only those phages that have attached to and then
infected bacteria, i.e., ‘Multiple infections,’” which will later be discussed on how to identify
phage activity in the lab [36]. This ratio can help determine how strongly a bacteriophage can act
against a target host bacteria. Unlike phage therapy, lysogenic phages, or temperate phages, are
the best for research on host-phage interactions. When lysogenic phages have a high MOI and
low virulence, then they are able to infect more cells at a time, without killing them, therefore
making research more productive. Having phages in the lysogenic cycle is most helpful for
researchers because of the nature of the phage’s virulence as well. One would not want to use
phages in the lytic cycle, due to their phages that exhibit a higher MOI in a shorter amount of
time, as seen in Figure 2.8, decreasing the amount of host-phage interactions that may be
successfully observed before the taking over of the site due to the quicker killing by virulent
phages. Certain phages are best for phage therapy and phage research studies. Virulent phages
from the lytic cycle are best for phage therapy, killing the infection quick and fast, and temperate
phages are best for research, killing the host more slowly and allowing researchers to observe
host-phage interactions longer. When researchers are able to do as such, they may answer more
questions about phages, leading on down the line to more discoveries about their medical uses
and how they may help humanity.
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Figure 2.8- In this diagram, from a study answering questions
about Anti-CRISPR genes and phages, where the split occurs,
one may view the difference between a low and high MOI
phage and the host’s effect over time [7].

Bacteriophages act upon bacterial cells in a 1:1 ratio, meaning the concentration of phage
and host bacteria also plays a key factor in discussing the overall effectiveness of a selected
bacteriophage for phage therapy. It is ideal for researchers and scientists to not only answer what
type of phage and bacteria to pair together, or genetically manipulate to be paired together, but
also how much concentration of phages and bacteria should be paired together. Since the amount
of host acts as the limiting factor being acted on by the phages, it is important to consider always
having enough phage and matching the 1:1 host/phage ratio as closely as possible to carry out the
mechanism of infection to completion. One may ask why phages can not simply be combined
and given to patients to cover all aspects of bacterial infection/disease, but thankfully some
researchers have already answered this question. To be frank, some researchers have concluded
that “although phage cocktails reduced the concentration of pathogens in [their] studies, further
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research is required to determine the correct dosing regimens and the most effective
combinations of phages targeting these pathogens” [27]. Even though some studies have been
done, such as the one about the California man mentioned before, unfortunately, phage-mixing is
considered a fairly new process to researchers, establishing the given need for more research,
unequivocally. All of these factors greatly tie into the future of phage research and phage therapy
and how these practices will be conducted safely and productively, leading to effective testing
and administering of bacteriophages, as seen in Figure 2.9, to those in need around the world.

Figure 2.9- Seen here as a microscopic depiction, bacteriophages
may someday become one of the most used treatments in medicine
as more questions are answered through research [14].
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Personal Research Experience: Playing a Part

Fortunately, I have been granted the opportunity to conduct bacteriophage research of my
own for my senior project. The main goal for this project: Compare the virulences of
bacteriophages Biskit (BK) and SketchMex (SM) and determine whether Biskit is a temperate
phage acting in the lysogenic cycle. For the duration of the project, three test subjects will be
focused on. The first subject, of course, used as a control, will only contain bacterial host cells
and no bacteriophages added. The bacteriophage, SketchMex will be used due to its known
capabilities of being a temperate phage in the lysogenic cycle; likewise, one test subject
containing only host, but no phage, will also be used as the control group for reference. The
phage in question, Biskit, will be cross-compared to SketchMex in regards to virulence and
growth curve characteristics, but also to the uninfected control flask, to establish a curve of best
fit for how the host interacts with its environment. If it is observed that Biskit is a temperate
phage, then as mentioned before, this is an ideal phage for research on host-phage interactions. If
one remembers, temperate phages in the lysogenic cycle are the best for phage research because
of their nature to infect multiple hosts without lysing them too fast, allowing time to be studied.
Since I am the pioneer student for a brand new era of phage research at Ouachita Baptist
University, the surface of what we can offer the world of phage research with this project will
only be scratched during this time; nonetheless, this research will go on to help future researchers
at Ouachita and other partnering schools/institutions to continue researching host-phage
interactions and how they can tell us even deeper about the way phages work and what they have
to offer. Even though conclusions that are publish-worthy may not be found among the data
presented now, later down the road, the data that I receive along with future data from others
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may cause later questions to be answered, providing a discovery or observation of significance
for the scientific community regarding phage research. Eventually, as more is learned about
temperate phages (hopefully Biskit in this case), then phage research itself will sky-rocket into
mainstream sciences. When phage research is able to be done with more subjects (host-range)
and for longer periods of time (temperance of lysogens), then it is most likely that positive
progress will ensue, assisting in making phage therapy better for all people. Research in this case
directly influences itself. As more questions are answered about phage research itself,
researchers can become more confident about the materials that they are working with and their
capabilities, perhaps even their medical capabilities for the future, prompting the FDA to loosen
strict rules and regulations regarding phage-use in the United States.
The overall plan of action to reach the goal for this project had been created. A simple
outline of the major steps had been:

1. Obtain phage lysates and titers.
a. Phage lysates are collected for stock in experimentation. Titers are used to
quantify pfu concentration as well as phage infectability.
2. Establish a growth curve for Uninfected.
a. Pour plates and assays are used to quantify colony concentration as well as
growth curve characteristics.
3. Establish a growth curve for Uninfected, Biskit, and SketchMex.
a. Titers, pour plates, and assays are used to quantify phage and colony
concentrations as well as growth curve characteristics for all three
subjects.
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4. Repeat #3.
5. Data interpretation and conclusions.

Though this outline was subject to change as far as preceding steps to each major step, it
was important to consider being timely and effective in experimentation, gathering data, and
discussing data with Dr. Plymale, all allowing me to stay on track to completing the goal in mind
for this particular project. As one may infer, it was also crucial to adhere to the guidelines for
procedures during experimentation. To officially begin my work, I first familiarized myself with
the subject matter at hand and polished my lab skills on the many interesting procedures that
were new to me. Nevertheless, I was up for the challenges, and genuinely excited to begin my
work in phage research.
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Step 1: Obtain Phage Lysates and Titers

Step 1 Goals and Procedures

To begin the overall project, testable bacteriophages were needed. The lysates of each
phage needed to be obtained to keep as stock throughout the semester to test. To obtain these
lysates, one must perform a lysation of webbed plates. Webbed plates are plates that have shown
an even spread of infection among host cells, giving the plate a “webbed” look. If the phages had
been at a higher concentration, then more clearing of a plate would take place. It is important to
obtain these lysates from concentrations that cause webbed plates because this is ideal for the
research project. The more a plate follows the “webbed” pattern, then the more likely the phage
is to be close to the ideal 1:1 ratio between phage and bacterial hosts. Of course, all bacterial
testing was done with Gordonia terrae for this project. The following procedure was used to
gather the lysates of Biskit and SketchMex:

Lysation Procedure

1. Prepare the workstation and gather materials.
2. Identify WEBBED plates (plate assay provided by Dr. Plymale beforehand).
3. Apply 8ml of sterile buffer solution to plates and set to the side in a safe place in the lab.
•Tip: It is important to have a buffer stock used only for phages and one only for bacteria
to decrease the chances of cross-contamination.
4. Wait 2-4 hours for plates to sit at room temperature.
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5. GENTLY swirl plates.
6. Suck up lysates and dispense them into a 50 mL conical tube for each phage.
7. Prepare a 0.22 μL filter with a 20 mL syringe.
8. Aspirate both lysates and filter into another 50 mL conical tube for each phage
•Tip: It is with the utmost importance that EVERYTHING is labeled EVERY TIME
something is used in the laboratory. This will greatly decrease the chance for errors.
9. Record final volumes and store lysates in the 4ºC fridge.

The lysations had successfully been carried out after instilling a wait time of 3 hours and 47
minutes. Approximately 5.0 mL of SketchMex lysate was obtained, and approximately 6.0 mL
of Biskit lysate was obtained. Now that the lysates had been collected to test, it was time to
perform serial dilutions along with full-plate titer assays to view two important aspects about the
phages, whether they can successfully infect the host bacteria, and at what concentration can
infection be reasonably seen and completed via countable plates. When a plate contains between
20 to 200 countable plaques, then this is considered the countable plate. Plaques show up as clear
spots dotted along the surface of the plate. They represent where one phage has successfully
lysed one bacterial cell.

Figure 3.1- Experimental Set-Up for Serial Dilution and Full Plate Titer Procedures.
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Now that the lysates had been collected, the phages were able to be diluted, combined
with the host, and viewed via a plaque assay across different plates. This would allow one to
view how the host and phages interact and how they do so at different concentrations. Below one
will find the procedures used for serial dilutions followed by the full plate titer procedure as well.
Though these are two separate procedures, they are completed one right after the other:

Serial Dilution Procedure (Set-Up in Figure 3.1)

1. Prepare the workstation and gather materials.
2. Set up 10-fold serial dilutions depending on desired concentrations.
3. Add 90 μL of phage buffer to each of the tubes.
4. Perform the dilutions.
a. Add 10 μL of each phage to the first appropriate tube.
b. Mix by pushing to the first stop about ten times while also tilting the tip
back-and-forth.
c. Transfer 10 μL to the next tube (i.e. 10⁻¹ to 10⁻² and so on) and mix well each
time.
•Tip: Make sure to use a different pipette tip for each transfer. The chances of error are
also decreased if one phage is diluted at a time.
5. Continue each dilution until completion.
6. Move on to Full Plate Titer Procedure.
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Full Plate Titer Procedure (Set-Up in Figure 3.1)

1. Prepare the workstation and gather materials, especially the tubes from the serial dilution
just performed.
2. Set out PYCA plates from the fridge, let them thaw, label plates.
3. Place 0.3 μL of Gordonia terrae bacteria stock into red-cap tubes, one for each dilution
for each phage. Make sure each tube is labeled to match the concentration.
•Tip: It is best to perform these titers focusing on one phage at a time.
4. Transfer 10 μL of each phage concentration to their respective host red-cap tube.
5. Allow 10 minutes for the combination between the phage and host in each red-cap tube.
6. Add 3 mL of top agar to the red-cap tube and directly pour onto the respectively labeled
plate. Swirl the plate covering the whole area.
•Tip: Perform this step starting with the lowest concentration (i.e. 10⁻⁸ to 10⁻⁷ and so on),
also be sure to be diligent in maneuvering to avoid the top agar from becoming too cool.
7. Let the plates sit for 20 minutes to settle and solidify.
•Tip: During this period, it has been found that this is the best time to switch to focusing
on the other phage being tested if any.
8. After the plates have settled, place them in the 30ºC incubator.
9. Check the plates for results 6 days later and count for plaques.
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Step 1 Titers for Biskit and SketchMex Results

Figure 3.2- Plate Titer 1 Qualitative Results (plaque assay and countable plates).

Figure 3.3- Plate Titer 2 Qualitative Results (plaque assay and countable plates).
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Figure 3.4- Plate Titer 3 Qualitative Results (plaque assay and countable plates).

Figure 3.5- Plate Titer 4 Qualitative Results (plaque assay and countable plates).
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Figure 3.6- Plate Titer 5 Qualitative Results (plaque assay and countable plates).

Figure 3.7- Full Plate Titer 1-3 Results Comparison.

Figure 3.8- Full Plate Titer 3-5 Results Comparison.
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Figure 3.9- Example calculation for determining pfu/cfu.

To begin experimentation for Step 1, Titers 1 and 2 were completed using the Serial
Dilution Procedure (Page 28) followed by the Full Plate Titer Procedure (Page 29). The final
calculation for the titers, in Figure 3.9, was able to provide the number of plaque-forming units
(pfu) per milliliter of media. This number assists in answering how much phage is in a sample,
which is to be reconsidered when manipulating phage concentrations to match host
concentrations in later experimentation. Two titers needed to be completed in order to increase
confidence and pinpoint the accuracy of the results to be given. One Titer completed would have
no comparison to prove significance, rendering it questionable. Being a set of procedures
detailed in length and technicality for one needing to learn through practice, the first set of two
titers had not produced significant results to carry on the project with. The results of Titers 1 and
2, in Figures 3.2 and 3.3, were not able to produce clear results that may have been observed
qualitatively, making quantitative data impossible to collect. Due to this, it was best decided to
move on to producing Titer 3, therefore providing results in the forms of qualitative data in
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Figure 3.4 and quantitative data in Figure 3.7, which also compares back to the Titers 1 and 2
quantitative sets of data. Due to the “pfu/mL” for Titers 1-3 being not precise to a realistic value
as well as not being accurate with one another, it was once again best decided to add not only
Titer 4 but also Titer 5, to provide more comparison to produce a significant value to move
forward with. As seen qualitatively in Figures 3.5 and 3.6, plates produced promising results
showing successful infection among bacteria from the applied phages. Quantitatively, in Figure
3.8, Titers 4 and 5 are also compared to the latest Titer 3, which had promising results itself.
Opposite that of the first titer comparison in Figure 3.7, the comparison between Titers 3 to 5
provided an accurate and precise value range to confidently move forward within the project. It
was also found that the 10⁻⁶ concentration for both phages Biskit and SketchMex was the best to
observe for determining the most accurate “pfu/ml” concentrations for later experimentation.
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Step 2: Establish a Growth Curve for Uninfected

Step 2 Goals and Procedures

Figure 4.1- Gordonia terrae stock used for experimentation.

The next objective that needed to be complete was the same goal as for Step 1, for now
that an accurate phage concentration had been established, it was appropriate to do the same for
the bacterial host, Gordonia terrae, seen in Figure 4.1. Similar to a full plate titer, the value for
the concentration of bacterial host cells was collected using pour plates. When using pour plates,
it is the same procedure as the Full Plate Titer Procedure, with the exception of using any
phages. The Serial Dilution Procedure beforehand is used with bacteria, allowing one to view
different concentrations of the bacterial host cells. The goal was to observe whether the bacteria
had the ability to grow and plot that growth graphically. The following procedures for pour plates
and the plate reader assay for the uninfected growth curve were used:
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Pour Plate Procedure

1. Prepare the workstation and gather materials.
2. Add 0.05g of Peptone, 0.75g of Yeast Extract, and 49.5 mL of ddH2₂O to the appropriate
glass container (Measurements for 50 mL Non-Agar PYCA Liquid).
3. Autoclave then mix.
4. Add 225 μL of 1M CaCl₂, 125 μL of 40% dextrose, 50 μL of Carbenicillin, 50 μL of
Cycloheximide, 50 μL of bacteria stock (making this liquid a 10⁻³ concentration).
5. Set up a Serial Dilution (Page 29), making different concentrations of bacteria and
creating a plaque assay of plate concentrations ranging from 10⁻³ to 10⁻⁶.
6. Check back for results in 4 days.

Plate Assay Plate Reader Procedure

1. Add 50 mL of newly made 10⁻³ concentration from the Pour Plate Procedure to two 250
mL filter-flasks, labeling them Af and Bf, as well as two 50 mL conical filter tubes
labeled Ct and Dt.
2. Label a 96-well plate and create the appropriate program for the plate reader.
3. Add 100 μL of Af to wells A1-A3, continue with Bf to wells B1-B3, and so on for Ct and
Dt.
•Tip: Continue later on starting with wells A4-A6.
4. Place the 96-well plate into the plate reader and run and save the program and results.
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5. Place the 96-well plate back into the package in a safe space. Place the flasks and tubes in
the 30ºC incubator.
6. Every 8 hours, at 8 am, 4 pm, and 12 am, return to the lab to repeat the procedure for a
week.
•Tip: BE PUNCTUAL IN TIMING. It is crucial that times do not exceed 15 minutes in
deviation, keeping data precise and accurate. It is best to take the 0h time at 12 am.
7. After a week, gather results and chart data, and dispose of flasks.

Step 2 Pour Plates and 96-Well Plates for Uninfected Results

Figure 4.2- Pour plates for Uninfected Step 2 results.
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Figure 4.3- 96-well plates used over the week for Step 2: Top-Left=0h-56h;
Top-Right=64h-120h; Bottom=120h, 224h, and 248h.

Figure 4.4- 96-Well Absorbance (OD600) Uninfected Growth Curve of Gordonia terrae results.
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To begin experimentation for Step 2, PYCA liquid containing no setting-agar needed to
be made to act as the liquid containing the bacteria being grown and observed within flasks and
tubes. The pour plates for the Uninfected, in Figure 4.2, provided a clear dilution across plates.
As opposed to the past titer, the concentrations only ranged from 10⁻³ to 10⁻⁶, saving lab time
making extra plates when there was an idea of the target concentration in mind from past
experimentation with Gordonia terrae. After making the pour plates, the 10⁻³ of Gordonia terrae
were aliquoted out to two 250 mLflasks as well as two 50 mL conical filter tubes. The reason for
the two different compartments, being a side-test, is for testing whether the bacteria grows easier
in the flasks or the tubes for future experimentation in Step 3. There were also two of each for
the already mentioned reasoning of making data more significant. The way the plate reader
collects data is by measuring absorbance. Within the plate reader, a beam of light having an
optical density of 600 nanometers is shone through each well that is measured, scanning the
whole well to completion, collecting an average absorbance for the well. When the light shines
through, a sensor at the bottom of the plate reader is able to measure how much of that 600 nm
light comes through. The less light to come through, then the more that has been absorbed by the
bacteria within the wells. The more bacteria that has grown in a well, then the higher the
absorbance value is, therefore establishing a direct relationship between the two. Collecting this
reading every 8 hours allowed the opportunity to plot this data over time, showing a growth
curve for the Uninfected subjects in Figure 4.4. The last three times were added and taken once
every 24 hours. This was to observe the subjects after an extended amount of time to better
understand their growth curve characteristics. The plates themselves can be qualitatively
observed in Figure 4.3, showing bacterial growth over time. A typical growth curve for bacteria
involves a period of rapid growth showing a constant increase, a plateau stage of no growth, and
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then a decrease with generations dying off. The whole shape can be simply described as a bell
curve with an extended and flattened middle instead of a peak. With that being said, such a curve
had successfully been observed in Figure 4.4 for the flasks, and a successful dilution had been
observed in Figure 4.2, showing that the 10⁻⁶ was the best concentration to carry forward with
for Step 3, similar to the phages’ target concentrations as well. The flasks ended up being the
ideal container for incubation because the tubes proved to be too small, causing a bacteria
caked-ring to form at the top, skewing data from what it should be, as seen successfully from the
flasks. The goals had now been accomplished for Step 2, answering questions about the bacterial
host as well as its growth curve characteristics. This allows the ability to continue on to Step 3,
which involves combining phage with host and using procedures from both Steps 1 and 2.
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Step 3: Establish a Growth Curve for Uninfected, Biskit, and SketchMex

Step 3 Goals and Procedures

Now that each of the necessary procedures had successfully been practiced and
completed, while also providing reference values, it was now time to combine it all into one
“Master Plan” to answer the main goal for this project: How do Biskit’s growth curve and
characteristics compare to SketchMex? The “Master Plan” consists of multiple steps, which are
full procedures themselves, with some changes to cater to Step 3:

“Master Plan” for Assay #1

1. Prepare the workstation and gather materials (Will need to be done multiple times).
2. Perform the Pour Plate Procedure (Page 37) with measurements for 600 mL non-agar
PYCA liquid, creating plates ranging from 10⁻³ to 10⁻⁶.
a. Check back for results in 4 days.
3. Perform titers of Biskit and SketchMex ranging from 10⁻⁵ to 10⁻⁷ using the Full Plate
Titer Procedure (Page 30).
a. Check back for results in 6 days.
4. Once results from pour plates and titers have been gathered, perform calculations setting
up phage and host to a 1:1 ratio.
5. Based on calculations gathered, add the following to their respective 250 mL filter-flasks:
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a. For Uninfected flasks A1 and A2- Add 50 mL of PYCA media and 50 μL of
bacteria stock to each flask.
b. For Biskit flasks B1 and B2- Add 50 mL of PYCA media, 50 μL of bacteria
stock, and 169.5 μL Biskit lysate to each flask.
c. For SketchMex flasks C1 and C2- Add 50 mL of PYCA media, 50 μL of bacteria
stock, and 139.3 μL of SketchMex lysate to each flask
6. Using the Plate Assay Plate Reader Procedure, set up 3 96-well plates, one each
representing Uninfected, Biskit, and SketchMex.
a. After labeling plates and creating the appropriate plate reader program, take the
0h time by aliquoting 100 μL of each flask into their respective wells: flask A1 to
wells A1-A3, and B1 to wells B1-B3, and so on for the other four flasks and their
96-well plates.
b. The next reading must use wells A4-A6 the next time for flask A1 and so on for
the other five flasks.
c. Continue this for the six flasks and their three 96-well plates
d. Once again, every 8 hours, at 8 am, 4 pm, and 12 am, return to the lab to repeat
the procedure for a week.
7. Once all data has been gathered, chart and draw conclusions for the next steps.
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Step 3 Procedures for Uninfected, Biskit, and SketchMex Results

Figure 5.1- Full plate titer results for Biskit and SketchMex (plaque assay and countable plates).

Figure 5.2- Pour plates for Uninfected Step 3 results.
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Figure 5.3- Step 3 flasks at hour 0.

Figure 5.4- Step 3 flasks at hour 352.
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Figure 5.5- 96-well plates used over the week for Step 3. All represent the hours from 0
to 56: Top-Left=Uninfected; Top-Right=Biskit; Bottom=SketchMex.

Figure 5.6- Host/Phage Concentration Comparison to make flasks.
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Figure 5.7- Step 3 growth curve results: Top-Left=Uninfected; Top-Right=Biskit;
Bottom-Left=SketchMex; Bottom-Right=All.
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For the beginning of Step 3, it was first necessary to regather data on the bacteria host
being tested. As seen in Figure 5.2, a successful set of pour plates had been created showing the
dilution of bacteria at 10⁻⁶ to have the countable plate once again. As seen in Figure 5.1, a
successful full plate titer had also been completed on phages Biskit and SketchMex. Along with
showing that the host and phage still successfully interacted with each other, the titers had also
shown that the plate concentration at 10⁻⁶ had also, once again, provided the countable plates to
use in future calculations. Now that the values representing the host and phage concentrations
had been gathered from Step 3, it was necessary to compare these values to past data from Steps
1 and 2 before continuing in experimentation. As seen in Figure 5.6, Step 3’s concentrations had
successfully followed with past values, allowing me to now perform the necessary calculations
for creating the tested flasks. Each of the flasks was to either contain only host, Biskit and host,
or SketchMex and host. In the flasks that contained both host and phage, plaque-forming unit
phage concentrations were manipulated to match colony-forming unit host concentrations to a
1:1 ratio. As before, two flasks were created for each of the three subjects to make data more
significant in the end. After each flask had been filled with their appropriate contents as
described in the “Master Plan” (Page 43), 96-well plates were created for each subject to
measure the absorbance for a week, establishing a growth curve for the three subjects:
Uninfected, Biskit, and SketchMex. Qualitative results of the three subjects can be seen in
Figures 5.3-5.5, showing the 96-well plates and flasks before and after experimentation. For all
flasks, in the beginning, no significant differences could be seen within the then clear-yellow
liquids, but at the final time taken, significant changes had been detected. When viewing flasks,
as seen in Figure 5.4, between flasks with phage versus flasks with no phage, there is a great
difference as the non-phage flasks had complete growth take-over as opposed to little or no
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growth in the infected flasks. The next difference is between Biskit and SketchMex, with
SketchMex showing a considerably higher average of growth within its flasks as opposed to
Biskit. The last noticeable difference, and perhaps the most surprising, is observed between both
flasks of SketchMex itself. Flask C2 for SketchMex had a larger amount of bacteria cell
clumping and growth, while flask C1 for SketchMex had no significantly visible differences than
how it had appeared at hour 0. Using the quantitative data (absorbances) from the plate readings,
as seen in Figure 5.7, growth curves were established showing the relationship between the
subjects themselves along with their two flasks, as well as an average of the two flasks for each
subject plotted against the other subjects. The Uninfected flasks, as before, had demonstrated a
typical curve seen for bacterial growth. As far as the flasks for Biskit and SketchMex, according
to the growth curves, a period of rapid growth never seems to have occurred with the bacteria,
causing the trend to stay low and steady throughout the duration of the experiment. As done
before with the plate readings, an outlier final time was taken at 352h, a full week after the last
time taken before that. This was necessary for drawing the best conclusion on how the whole
growth curve is characterized over an even longer period of time than usually plotted. Due to the
timing of the school semester as well as the results displayed, lab experimentation had finished
for my own personal research, but much was to be considered for the future of the project.
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Final Thoughts and Conclusions

Conclusions and Future of the Project

Based on the overall growth curve results obtained from Step 3 as well as the end of the
semester approaching, it was decided to pause the project and go back to the drawing board.
Unfortunately, looking at the graphs in Figure 5.7, Biskit and SketchMex had prevented their
bacterial hosts from displaying any observable growth curve. Since there were no growth curves
established with the phages, the project's main goal could not be completed at this time, which
involves viewing and comparing the growth curves of Biskit and SketchMex themselves. After
speaking with Dr. Plymale, my theory on the matter is that the moieties between host and phage
react with one another differently than at a 1:1 ratio. Phages most likely need to be decreased in
concentration, instead, for example, providing a host/phage ratio of 2:1 or 4:1. This would cause
a more conservative amount of phages to be combined with each host, therefore not
over-powering their hosts, allowing host/phage subjects to establish a viewable growth curve that
may be studied and used as a reference for future trials such as that would have been done in
Step 4. Next in future experimentation for the project, I would suggest manipulating the 1:1
moiety as explained before. The set-up would be identical to that of Step 3 except subjects
themselves would also be split up into different moieties as opposed to the only 1:1 ratio that had
been viewed for my personal research. Instead of 6 flasks, 18 would be used in this case,
allowing one to also observe a range of host/phage ratios such as 1:1, 2:1, and 4:1. From this
base test, more can be figured out about how much moiety plays into host/phage interactions,
leading to even better manipulation of the moieties to establish a successful growth curve that
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may be viewed and studied. After such has been completed, then similar trials may be completed
to make data credible, allowing one to answer the original question for this project: How do the
virulences of bacteriophages Biskit and SketchMex compare, and can it be determined whether
Biskit is a temperate phage acting in the lysogenic cycle? Though my research is over, the
project triumphantly continues, waiting to answer questions about the phage Biskt and
host/phage interactions in general.

Future of Phage Research

Across the country, many like myself are performing phage research to better answer
questions about bacteriophages and how they may help the world. Though many questions have
been answered by researchers, the FDA still poses many regulations on phage research and use
in the United States. On a realistic note, it may take years for the FDA to offer any significant
changes to the phage research community, as they have been known to be strict in the past. This
fact does not change the importance of phage research, for it has already proven to be useful for
phage therapy, which has medically saved millions of lives from antibiotic-resistant bacterial
infection. Sooner or later, antibiotic resistance will prevail among the human population, causing
devastation to the masses. Hopefully, by that time, phage research will have been allowed to
answer more questions about the medical use for bacteriophages, providing an alternative that
may pave the road for the future of medicine. I aspire to claim that my research will go on to
assist in answering bigger questions about host/phage interactions at Ouachita Baptist University
and beyond. The more that is learned and answered about bacteriophages, then the more ability
we will have to use them to treat some of the world’s biggest medical problems today.
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